A Study of MEDI7352 in Painful Osteoarthritis of the Knee
CompletedPhase 1NCT02508155
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to assess the safety, drug levels and effects on the body of MEDI7352, in subjects with painful osteoarthritis of the knee.
Study details
- Official title
- A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee
- Conditions
- Interventions
- Biological: MEDI7352 for IV infusion
- Biological: Placebo for IV infusion
- Biological: MEDI7352 for Subcutaneous Injection
- Biological: Placebo for Subcutaneous Injection
- Sponsor
- AstraZeneca
- Start date
- 2015-11-17
- Primary completion
- 2020-12-23
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- Germany, Sweden, United Kingdom
- Total sites listed
- 6
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Male and female subjects with painful osteoarthritis (OA) of the knee. Female subjects must be postmenopausal or surgically sterile. * Body weight between 50kg and 145kg * Willing and able to comply with the requirements of the protocol Exclusion Criteria: * Current treatment with another biologic therapeutic agent * Current of historical diagnosis of RA * Current diagnosis of an immunological condition that is associated with another form of arthritis in addition to OA, including traumatic arthritis or a seronegative spondyloarthropathy * At risk of destructive arthropathy, including Rapidly Progressive Osteoarthritis (RPOA), osteonecrosis, spontaneous osteonecrosis of the knee, subchondral insufficiency fractures, hip dislocation and pathological fracture * Presence of clinically significant neuropathy or other clinically significant disorder involving abnormal peripheral sensation. * Current serious or unstable clinically important illness.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT02508155